Идёт
Фаза III
РИСАНКИЗУМАБ (ABBV-066) · AbbVie Inc.
A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease